Sanofi CEO Chris Viehbacher has told investors that the company expects growth in 2012 as it approaches the end of its ‘patent cliff’ and recent acquisitions begin to perform.

Over the past three years, the French pharmaceutical firm has diversified and now expects an increasing share of its turnover to be produced in emerging markets, diabetes medications, human vaccines, consumer healthcare and innovative products.

Viehbacher expects 66% of Sanofi turnover to be generated by these platforms in 2011, rising to 80% by 2015.

Since January 2009, Sanofi has spent €23bn on the acquisition of 23 businesses, including some in the animal health and generics sectors.